Select Bibliography

Filter by any of these (after searching):

Collyar, D.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB)

Katz, M. L. , Archer, L. E. , Peppercorn, J. M. , Kereakoglow, S. ... - ASCO - J Clin Oncol - 2010

Abstract - No-Endpoint - Other - Patient Adv - No Study Assigned

Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET): a prospective randomized trial for low-risk DCIS

Lynch, T. , Partridge, A. , Thompson, A. , Frank, E. , Pinto, D. ... - SABCS - Cancer Res - 2020

Abstract - No-Endpoint - Trial-Description-Only - Breast - AFT-25

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

Sikov, W. , Berry, D. , Perou, C. , Singh, B. , Cirrincione, C. ... - SABCS - Cancer Res - 2013

Abstract - Primary - Primary - Breast - CALGB-40603

Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer

Sikov, W. , Perou, C. M. , Golshan, M. , Collyar, D. , Berry, D. A. ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Preliminary - Breast - CALGB-40603